SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Viridien (CGGYY) trades at a trailing P/E of 22.9, forward P/E of 2.6. Trailing earnings yield is 4.36%, forward earnings yield 39.22%.
Criteria proven by this page:
- VALUE (75/100, Pass) — P/E is below market average (22.9); earnings yield beats bond yields (4.36%).
- Forward P/E 2.6 (down from trailing 22.9) — analysts expect earnings to grow, which would improve the valuation.
- Trailing Earnings Yield 4.36% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 39.22% as earnings recover.
Overall SharesGrow Score: 61/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CGGYY
Valuation Multiples
P/E (TTM)22.9
Forward P/E2.6
PEG RatioN/A
Forward PEG0.00
P/B Ratio0.00
P/S Ratio0.28
EV/EBITDA0.0
Per Share Data
EPS (TTM)$1.80
Forward EPS (Est.)$16.20
Book Value / Share$0.00
Revenue / Share$150.00
FCF / Share$0.00
Yields & Fair Value
Earnings Yield4.36%
Forward Earnings Yield39.22%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$-4,943.00 |
$3.1B |
$-1.15B |
-37.3% |
| 2015 |
$-6,207.00 |
$2.1B |
$-1.45B |
-69% |
| 2016 |
$-1,326.00 |
$1.2B |
$-573.4M |
-47.9% |
| 2017 |
$-1,118.00 |
$1.32B |
$-514.9M |
-39% |
| 2018 |
$-16.00 |
$1.19B |
$-101.6M |
-8.5% |
| 2019 |
$18.00 |
$1.36B |
$126.3M |
9.3% |
| 2020 |
$-53.00 |
$886.7M |
$-375.7M |
-42.4% |
| 2021 |
$-26.00 |
$1.06B |
$-181.7M |
-17.1% |
| 2022 |
$9.28 |
$927.4M |
$66.3M |
7.1% |
| 2023 |
$1.80 |
$1.08B |
$12.9M |
1.2% |
